Autologous CIK cell treatment of advanced non-small cell lung cancer 30 cases.docVIP

 PAGE \* MERGEFORMAT 7 Autologous CIK cell treatment of advanced non-small cell lung cancer 30 cases [Abstract] Objective To investigate the autologous CIK cell treatment of advanced non-small cell lung cancer. Methods of our department 30 patients with advanced non-small cell lung cancer patients with autologous CIK cell treatment. Results of 26 cases of partial remission, response rate 56.60%, the median survival was 8.5 months. Conclusions Autologous CIK cells in patients with advanced non-small cell lung cancer patients can prolong survival, improve patient quality of life. [Keywords:] autologous CIK cells, non-small cell lung cancer Non-small cell lung cancer is a common lung cancer, lung cancer accounts for about 80% to 85%, surgery is the early and mid-term of choice for non-small cell lung cancer treatment, but about 70% to 80% of patients with lung cancer diagnosis has been late, lost opportunities for surgical treatment, chemotherapy and radiotherapy as primary treatment, however, there are still about 10% of cases could not adhere to the chemotherapy or unwilling to accept chemotherapy. because these methods in the treatment of diseases, often at the same time affect immune function. We have since September 2006 ~ December 2008 not willing to accept between 30 cases of radiotherapy and chemotherapy in patients with advanced non-small cell lung cancer, to take cytokine-induced killer cells (cytokine induced killer cells, CIK) treatment have better clinical results, are reported below. 1 Materials and Methods 1.1 General Information Or by histology and cytology confirmed or B non-small cell lung cancer, 30 cases had clinically measurable lesions, quality of life score (KPSgt; = 50 points, expected survival greater than 1 month, a certain bone marrow reserve. including 26 males and 4 females, aged 38 to 81 years, mean age 58.3 years, 18 cases of squamous cell carcinoma, adenocarcinoma 12 cases, B 13 cases, of 17 cases. 1.2 Tre